All In Biotech

Drug Trial Radar · NCT05488340

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

A Phase 2, Double-blind, Randomized, Active-controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of LBP-EC01 in the Treatment of Acute Uncomplicated Urinary Tract Infection Caused by Drug Resistant E. Coli

Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 318 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

318

Planned (sponsor's estimate)

Start

Jul 13, 2022

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Locus BiosciencesIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Aug 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.

Conditions

  • Urinary Tract Infections

Interventions

  • LBP-EC01 0.1 x IV doseDrug

    Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.

  • LBP-EC01 0.01x IV DoseDrug

    Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.

  • LBP-EC01 IV Infusion DoseDrug

    Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.

  • PlaceboDrug

    Dose regimen selected from Part 1 of placebo (Tris buffer).

  • LBP-EC01Drug

    Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.

  • TMP/SMXDrug

    TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Levels of LBP-EC01 in urine and blood measured by quantitative plaquing assay across the treatment period and over 48 h after the last doseTime frame: Day 1 to Day 5
  2. Part 2: Proportion of patients with resolution of clinical symptoms and microbiologic response of uUTI caused by drug resistant E. coli as defined at Day 10 test of cure (TOC).Time frame: Day 10

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site 138

    Fresno, California · Completed

  • Research Site 131

    Lancaster, California · Recruiting

  • Research Site 123

    Los Angeles, California · Recruiting

  • Research Site 125

    Montebello, California · Completed

  • Research Site 152

    Murrieta, California · Recruiting

  • Research Site 137

    San Diego, California · Recruiting

  • Research Site 126

    Tustin, California · Recruiting

  • Research Site 102

    Doral, Florida · Recruiting

  • Research Site 151

    Hialeah, Florida · Recruiting

  • Research Site 140

    Jensen Beach, Florida · Completed

  • Research Site 103

    Miami, Florida · Recruiting

  • Research Site 149

    Miami, Florida · Recruiting

  • Research Site 153

    Ocala, Florida · Recruiting

  • Research Site 120

    Boston, Massachusetts · Completed

  • Research Site 154

    St Louis, Missouri · Recruiting

  • Research Site 145

    Raleigh, North Carolina · Recruiting

  • Research Site 118

    Winston-Salem, North Carolina · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.